Orexo AB: First Patient Dosed in New Study on Long-Term Adherence to Treatment of Opioid Dependence With Zubsolv®
8/7/2013 9:44:58 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
UPPSALA, Sweden--(BUSINESS WIRE)--Regulatory News: Orexo today announces that the first patient has been dosed in a study designed to document the long-term effects of Zubsolv® on the retention and adherence to opioid replacement therapy. Other aspects that will be assessed and documented include opioid cravings, effects on withdrawal symptoms, tolerability and how treatment affects patients’ quality of life. In addition, the study will enable Orexo to analyze the impact of Zubsolv on health economic parameters such as cost of treatment, clinical resource utilization and societal benefits.
Help employers find you! Check out all the jobs and post your resume.
comments powered by